CapsoVision, Inc. (CV) is a Saratoga, California-based commercial-stage medical technology company that develops capsule endoscopy systems for imaging the gastrointestinal tract. Its CapsoCam Plus capsule provides a 360-degree panoramic view of the small bowel, and the company received FDA clearance on September 25 for an AI-assisted reading module it launched in the U.S. on November 2.
In Thursday's session, the stock traded at $6.43, down $0.39, or 5.72%, from the prior close of $6.82. The move was unambiguously negative, and no verified news catalyst was found to explain it. The decline looks technical in nature: a give-back after a sharp three-day advance, in a thin, micro-cap name still digesting a soft quarterly report.
No verified news or fundamental catalyst found ahead of Thursday's decline. There was no press release, no new SEC filing beyond those tied to the November 12 quarterly report, and no rating change. Coverage remains sparse, with only two analysts publishing estimates.
The most probable explanation is mechanical. CapsoVision bottomed at $6.03 on November 13, one day after earnings, then rallied 7.3%, 2.8% and 2.6% across the next three sessions to $6.82. That 13% bounce arrived without incremental news, and Thursday's reversal retraced roughly a third of it — a pattern consistent with short-term profit-taking rather than a change in fundamentals. With average turnover near 120,000–170,000 shares per day, order flow of even modest size can move the quote several percent, and the stock has recorded 18 sessions with absolute moves above 4% in the past three months alone.
The November 12 report remains the dominant fundamental reference point for the stock. Third-quarter revenue of $3.57 million rose just 0.8% year over year and missed consensus near $3.76 million, while GAAP loss per share of $0.15 came in a penny wider than expected. Gross margin fell to 49% from 54%, pressured by higher flash-memory costs, an inventory obsolescence charge, and stock-based compensation.
The filing also disclosed substantial doubt about the company's ability to continue as a going concern, alongside an at-the-market program of up to $100 million and share count growth of 14.4% so far this year. Cash stood at $21.8 million at September 30, including roughly $17.8 million in net proceeds from a September offering. That financing backdrop keeps dilution risk in the foreground for holders and tends to cap rallies in unprofitable micro-caps.
There was no sector-wide event that explains the drop. The move was stock-specific and did not track a corresponding announcement from capsule-endoscopy peers. Turnover in recent sessions has been unremarkable — 75,040 shares on November 16, 73,403 on November 17 and 94,528 on November 18 — so there is little evidence of institutional repositioning.
Technically, the stock failed to hold above the $6.82–$6.87 band that capped it on November 18 and slipped toward the $6.36 area that marked the November 3 low. The $6.03 level from November 13 remains the nearest meaningful support, with resistance at the October 23 high of $7.18. At $6.43 the shares sit below their 20-day average near $6.62, are about 58% below the 52-week high of $15.37, and are down roughly 33% year to date.
The score is measured on a 0–100 scale, where 0 means no meaningful news and a move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, rare price move. CapsoVision earns 14 out of 100.
Verified news was weak: nothing new arrived on Thursday, and the only nearby catalyst was a quarterly report from the prior week that was routine in size relative to a $345 million market capitalization. The price move was also only about 2.3 times the stock's typical daily swing of 2.5%, and moves of similar or larger magnitude occurred eight times in the last 69 sessions. Both components score low, producing a modest total.
The central scheduled event is the planned submission of the second-generation CapsoCam Colon 510(k) application before year-end 2026, following completion of its pivotal study enrollment and data collection. Management has said the statistician is finalizing primary and secondary endpoint data before drafting the filing. Any delay would be meaningful, given that an earlier colon application was withdrawn after regulator questions.
Fourth-quarter results, expected in March on the prior-year cadence, will be the first real read on the AI Highlights launch, with consensus revenue near $4.6 million and full-year 2026 revenue around $14.6 million. Investors will also watch gross margin recovery after the flash-memory pressure, operating expense discipline now that colon trial costs should decline, and cash balances against an average quarterly burn above $7 million. Two covering analysts carry Buy-equivalent ratings, though estimates are built on a very small sample. Dilution from the at-the-market facility and the going-concern disclosure remain the clearest risks.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page lets investors compare live approaches side by side rather than relying on a single model. It is a practical starting point for anyone screening systematic strategies in a fast-moving tape, and worth a look before the next session opens.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CV declined for three days, in 56 of 71 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CV as a result. In 17 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for CV turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 9 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
CV moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CV crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 14 of 15 cases where CV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +5.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CV advanced for three days, in 65 of 75 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
CV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 29 of 34 cases where CV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. CV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CV's P/B Ratio (25.542) is slightly higher than the industry average of (4.142). P/E Ratio (-5.672) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (21.598) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices